Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Checkpoint Therapeutics

18/03/2025 12:39

Checkpoint Therapeutics Inc CKPT.OQ CKPT.O is expected to show a fall in quarterly revenue when it reports  results on March 20 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Checkpoint Therapeutics Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Checkpoint Therapeutics Inc is $4.80​, above​ its last closing price of $3.99. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.15
-0.15
-0.23
Missed
-56.8
Jun. 30 2024
-0.30
-0.30
-0.18
Beat
41
Mar. 31 2024
-0.29
-0.27
-0.33
Missed
-20.7​
Dec. 31 2023
-0.54
-1.10
Missed
-102.5
​​Sep. 30 2023
-0.75
-0.76
-0.29
Beat
61.8
Jun. 30 2023
-0.77
-0.78
-1.05
Missed
-34.6​
Mar. 31 2023
-1.09
-1.07
-0.89
Beat
16.6
Dec. 31 2022
-1.30
-1.31
-2.29
Missed
-75.3

This summary was machine generated March 18 at 12:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)